Pulmonary function in patients with Huntington’s Disease

BMC Pulmonary Medicine

Kazunori Nosaka¹  Mel Ziman³  Travis Cruickshank²  Alvaro Reyes² 

[1] School of Exercise and Health Sciences, Centre for Exercise and Sports Science Research, Edith Cowan University, Joondalup, WA, Australia;School of Medical Sciences Edith Cowan University, 270 Joondalup Drive, Joondalup, 6027, WA, Australia;School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, WA, Australia

关键词: Huntington’s disease;    Pulmonary function;   

Others  :  862880
DOI  :  10.1186/1471-2466-14-89

 received in 2014-01-15, accepted in 2014-05-20,  发布年份 2014

【 摘 要 】

Background

Huntington’s disease (HD) is a neurodegenerative disorder characterized by progressive motor, cognitive and psychiatric disturbances. Chest muscle rigidity, respiratory muscle weakness, difficulty in clearing airway secretions and swallowing abnormalities have been described in patients with neurodegenerative disorders including HD. However limited information is available regarding respiratory function in HD patients. The purpose of this study was to investigate pulmonary function of patients with HD in comparison to healthy volunteers, and its association with motor severity.

Methods

Pulmonary function measures were taken from 18 (11 male, 7 female) manifest HD patients (53 ± 10 years), and 18 (10 male, 8 female) healthy volunteers (52 ± 11 years) with similar anthropometric and life-style characteristics to the recruited HD patients. Motor severity was quantified by the Unified Huntington’s Disease Rating Scale-Total Motor Score (UHDRS-TMS). Maximum respiratory pressure was measured on 3 separate days with a week interval to assess test-retest reliability.

Results

The test-retest reliability of maximum inspiratory and expiratory pressure measurements was acceptable for both HD patient and control groups (ICC ≥0.92), but the values over 3 days were more variable in the HD group (CV < 11.1%) than in the control group (CV < 7.6%). The HD group showed lower respiratory pressure, forced vital capacity, peak expiratory flow and maximum voluntary ventilation than the control group (p < 0.05). Forced vital capacity, maximum voluntary ventilation and maximum respiratory pressures were negatively (r = -0.57; -0.71) correlated with the UHDRS-TMS (p < 0.05).

Conclusion

Pulmonary function is decreased in manifest HD patients, and the magnitude of the decrease is associated with motor severity.

【 授权许可】

   
2014 Reyes et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Roos RA: Huntington’s disease: a clinical review. Orphanet J Rare Dis 2010, 5:40. BioMed Central Full Text
• [2]Sturrock A, Leavitt BR: The clinical and genetic features of Huntington disease. J Geriatr Psychiatry Neurol 2010, 23:243-259.
• [3]Gil JM, Rego AC: Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci 2008, 27:2803-2820.
• [4]Mehanna R, Jankovic J: Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord 2010, 16:628-638.
• [5]Jones U, Enright S, Busse M: Management of respiratory problems in people with neurodegenerative conditions: a narrative review. Physiotherapy 2012, 98:1-12.
• [6]Jones U, Enright S, Busse M, Rosser A: J11‚ÄÖA pilot study on respiratory function in people with huntington’s disease. J Neurol Neurosurg Psychiatry 2010, 81:A42-A43.
• [7]Heemskerk AW, Roos RA: Dysphagia in Huntington’s disease: a review. Dysphagia 2011, 26:62-66.
• [8]Kagel MC, Leopold NA: Dysphagia in Huntington’s disease: a 16-year retrospective. Dysphagia 1992, 7:106-114.
• [9]Zinzi P, Salmaso D, De Grandis R, Graziani G, Maceroni S, Bentivoglio A, Zappata P, Frontali M, Jacopini G: Effects of an intensive rehabilitation programme on patients with Huntington’s disease: a pilot study. Clin Rehabil 2007, 21:603-613.
• [10]Polatli M, Akyol A, Cildag O, Bayulkem K: Pulmonary function tests in Parkinson’s disease. Eur J Neurol 2001, 8:341-345.
• [11]Haas CF, Loik PS, Gay SE: Airway clearance applications in the elderly and in patients with neurologic or neuromuscular compromise. Respir Care 2007, 52:1362-1381. discussion 1381
• [12]Thompson JA, Cruickshank TM, Penailillo LE, Lee JW, Newton RU, Barker RA, Ziman MR: The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington’s disease: a pilot study. Eur J Neurol 2013, 20:1325-1329.
• [13]Evans JA, Whitelaw WA: The assessment of maximal respiratory mouth pressures in adults. Respir Care 2009, 54:1348-1359.
• [14]Dimitriadis Z, Kapreli E, Konstantinidou I, Oldham J, Strimpakos N: Test/retest reliability of maximum mouth pressure measurements with the MicroRPM in healthy volunteers. Respir Care 2011, 56:776-782.
• [15]Black LF, Hyatt RE: Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969, 99:696-702.
• [16]American Thoracic Society/European Respiratory Society: ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med 2002, 166:518-624.
• [17]Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
• [18]Stanojevic S, Wade A, Stocks J, Hankinson J, Coates AL, Pan H, Rosenthal M, Corey M, Lebecque P, Cole TJ: Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008, 177:253-260.
• [19]Thompson BR, Stanojevic S, Abramson MJ, Beasley R, Coates A, Dent A, Eckert B, James A, Filsell S, Musk AW, Nolan G, Dixon B, O'Dea C, Savage J, Stocks J, Swanney M, Hall GL: The all-age spirometry reference ranges reflect contemporary Australasian spirometry. Respirology 2011, 16:912-917.
• [20]Nunn AJ, Gregg I: New regression equations for predicting peak expiratory flow in adults. BMJ 1989, 298:1068-1070.
• [21]Smeltzer SC, Lavietes MH: Reliability of maximal respiratory pressures in multiple sclerosis. Chest 1999, 115:1546-1552.
• [22]Parkes G, Greenhalgh T, Griffin M, Dent R: Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008, 336:598-600.
• [23]Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. the lung health study. Am J Respir Crit Care Med 2000, 161:381-390.
• [24]Willemse BW, Postma DS, Timens W, ten Hacken NH: The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004, 23:464-476.
• [25]Sathyaprabha TN, Kapavarapu PK, Pall PK, Thennarasu K, Raju TR: Pulmonary functions in Parkinson’s disease. Indian J Chest Dis Allied Sci 2005, 47:251-257.
• [26]Trebbia G, Lacombe M, Fermanian C, Falaize L, Lejaille M, Louis A, Devaux C, Raphael JC, Lofaso F: Cough determinants in patients with neuromuscular disease. Respir Physiol Neurobiol 2005, 146:291-300.
• [27]Boitano LJ: Management of airway clearance in neuromuscular disease. Respir Care 2006, 51:913-922. discussion 922–914
• [28]Lomauro A, Romei M, D’Angelo MG, Aliverti A: Determinants of cough efficiency in Duchenne muscular dystrophy. Pediatr Pulmonol 2013, 49:357-365.
• [29]Roze E, Bonnet C, Betuing S, Caboche J: Huntington’s disease. Adv Exp Med Biol 2010, 685:45-63.
• [30]Gordon AM, Quinn L, Reilmann R, Marder K: Coordination of prehensile forces during precision grip in Huntington’s disease. Exp Neurol 2000, 163:136-148.
• [31]Delval A, Krystkowiak P, Blatt JL, Labyt E, Bourriez JL, Dujardin K, Destee A, Derambure P, Defebvre L: A biomechanical study of gait initiation in Huntington’s disease. Gait Posture 2007, 25:279-288.
• [32]Thompson PD, Berardelli A, Rothwell JC, Day BL, Dick JP, Benecke R, Marsden CD: The coexistence of bradykinesia and chorea in Huntington’s disease and its implications for theories of basal ganglia control of movement. Brain 1988, 111(Pt 2):223-244.